Emerging Safety Issues in Pharmacovigilance

Introduction

Pharmacovigilance systems are designed to identify, evaluate and manage safety concerns associated with medicinal products. Most potential concerns are managed through routine pharmacovigilance activities such as signal detection, signal validation and signal assessment. Some situations, however, require more urgent attention because of their potential impact on public health.

The concept of an Emerging Safety Issue (ESI) was introduced to support rapid identification and escalation of important safety concerns that may require immediate regulatory awareness or action. The purpose of an ESI process is not to replace routine signal management activities but to ensure that particularly significant concerns receive appropriate attention without unnecessary delay.

Emerging safety issues may arise from signals, but not all signals become emerging safety issues. Similarly, an emerging safety issue may arise from information sources other than formal signal management activities.

Understanding this distinction is important because emerging safety issues are often associated with accelerated assessment, senior management visibility and regulatory communication requirements.

Regulatory Context

Within the European Union, emerging safety issues are discussed within several pharmacovigilance guidance documents, including GVP Module IX and guidance relating to Periodic Safety Update Reports and risk management systems.

The concept exists because some safety concerns cannot wait for routine reporting cycles or standard governance processes.

Regulators may require immediate awareness of information that could significantly affect:

• Patient safety
• Product use
• Benefit-risk balance
• Public health decision-making

Consequently, organisations should maintain procedures describing how emerging safety issues are identified, escalated and communicated.

What Is an Emerging Safety Issue?

An emerging safety issue is a safety concern that may require urgent evaluation or regulatory awareness because of its potential significance.

The precise definition may vary slightly between organisations and procedures. However, the common principle is that an emerging safety issue represents information that may have an important impact on the safety profile or benefit-risk balance of a medicinal product.

The concept should be understood operationally rather than purely academically.

The key question is often:

Does this information require accelerated attention because waiting for routine processes may be inappropriate?

If the answer may be yes, escalation as a potential emerging safety issue may be warranted.

Emerging Safety Issues Versus Safety Signals

Emerging safety issues and safety signals are closely related but distinct concepts.

A signal represents information suggesting a potential association that warrants further evaluation.

An emerging safety issue represents a concern that may require urgent awareness, assessment or action.

Many emerging safety issues originate from signal management activities. For example, a validated signal involving a serious and potentially life-threatening adverse reaction may be escalated as an emerging safety issue.

However, emerging safety issues may also arise from:

• Clinical studies
• Regulatory communications
• Manufacturing issues with safety implications
• Published scientific findings
• Major epidemiological observations

The distinction is therefore based primarily on urgency and potential impact rather than source.

Characteristics of Emerging Safety Issues

There is no universal checklist that automatically determines whether a concern should be considered an emerging safety issue.

Nevertheless, several characteristics commonly influence escalation decisions.

These may include:

• Potentially serious public health consequences
• Significant changes in benefit-risk balance
• Previously unrecognised serious risks
• Rapidly evolving information
• Potential need for urgent regulatory action
• Significant media or public attention

Professional judgement remains important when determining whether escalation is appropriate.

Sources of Emerging Safety Issues

Emerging safety issues may arise from a wide range of information sources.

Spontaneous adverse reaction reports remain an important source, particularly when unusual patterns or clusters are identified.

Clinical studies may also generate emerging safety issues. In some situations, study findings provide the first indication of a previously unrecognised risk.

Scientific literature may identify concerns requiring urgent evaluation, particularly when published findings involve serious outcomes or clinically important associations.

Regulatory communications from other authorities can also generate emerging safety issues when they indicate concerns relevant to authorised products.

In practice, organisations should maintain processes capable of identifying emerging concerns regardless of the original source.

Examples of Potential Emerging Safety Issues

Examples that may warrant consideration as emerging safety issues include:

Newly Identified Fatal Adverse Reactions

Information suggesting a previously unrecognised fatal reaction may require urgent evaluation.

Significant Changes in Known Risks

New information indicating substantially greater severity or frequency of a known risk.

Important Clinical Trial Findings

Safety findings that could influence product use or regulatory decision-making.

Major Benefit-Risk Concerns

Information suggesting that the overall benefit-risk balance may have changed.

Safety Concerns Affecting Large Patient Populations

Issues with potential widespread public health implications.

Not all such observations will ultimately be classified as emerging safety issues, but they commonly trigger escalation discussions.

Identification and Escalation

Identification of emerging safety issues depends upon effective pharmacovigilance processes.

Potential concerns may be identified through:

• Signal management activities
• Literature surveillance
• Clinical development programmes
• Medical review
• Regulatory intelligence activities

Once identified, escalation pathways should be clearly defined.

Procedures should specify:

• Escalation criteria
• Responsible functions
• Communication timelines
• Documentation requirements

The objective is to ensure that potentially important concerns become visible to appropriate decision-makers.

Role of Governance

Governance is particularly important for emerging safety issues because decisions often need to be made within compressed timelines.

Organisations commonly utilise:

• Safety management teams
• Product safety committees
• Signal review groups
• Executive safety governance forums

Governance arrangements should facilitate rapid review while maintaining scientific rigour.

Documentation of decisions remains important even when timelines are accelerated.

Regulatory Communication

Certain emerging safety issues may require communication with regulatory authorities.

The specific requirements depend upon:

• Jurisdiction
• Product type
• Nature of the concern
• Regulatory obligations

Timely communication is important because regulators may need to assess whether additional action is required to protect public health.

Procedures should therefore define how regulatory reporting obligations are evaluated when emerging safety issues are identified.

Relationship to Benefit-Risk Evaluation

Emerging safety issues frequently have implications for benefit-risk evaluation.

Not every emerging safety issue alters the benefit-risk balance. However, many involve information that may influence understanding of either risks or benefits.

Assessment should therefore consider:

• Magnitude of potential risk
• Clinical significance
• Affected populations
• Existing risk minimisation measures
• Therapeutic context

This evaluation helps determine whether additional actions are required.

Role of the QPPV

The QPPV should maintain visibility of significant emerging safety issues affecting products within their area of responsibility.

The QPPV is not necessarily responsible for identifying every potential emerging safety issue personally. However, governance systems should ensure that important concerns are escalated appropriately.

Inspectors commonly expect the QPPV to understand:

• How emerging safety issues are identified
• How escalation occurs
• How decisions are documented
• How regulatory communications are managed

The QPPV should also be aware of significant emerging safety issues that may affect product safety profiles or regulatory obligations.

Emerging Safety Issues During Inspections

Inspection teams frequently examine how organisations manage emerging safety issues.

Areas commonly reviewed include:

• Procedures
• Escalation pathways
• Governance records
• Communication processes
• Decision-making rationale

Inspectors often focus on whether potentially significant concerns can be identified and escalated rapidly.

Deficiencies are commonly associated with governance weaknesses, unclear responsibilities or poor documentation.

Common Challenges

Several challenges arise when managing emerging safety issues.

The first is uncertainty. Information available at the time of escalation is often incomplete.

A second challenge is proportionality. Organisations must avoid both over-escalation and under-escalation.

A third challenge is communication. Significant concerns frequently involve multiple stakeholders, including pharmacovigilance, regulatory affairs, clinical teams and senior management.

Finally, organisations must balance urgency with scientific rigour. Accelerated timelines should not compromise the quality of evaluation.

Key Takeaways

Emerging safety issues are safety concerns that may require urgent evaluation, escalation or regulatory awareness because of their potential significance.

Although many emerging safety issues originate from signal management activities, the concepts are not interchangeable.

Emerging safety issues may arise from spontaneous reports, clinical studies, literature findings, regulatory communications or other sources.

Effective management requires clear escalation pathways, appropriate governance, timely communication and adequate documentation.

The QPPV should maintain visibility of significant emerging safety issues and understand how they are managed within the pharmacovigilance system.

References

1. EMA Good Pharmacovigilance Practices (GVP) Module IX – Signal Management.
2. EMA Good Pharmacovigilance Practices (GVP) Module V – Risk Management Systems.
3. EMA Good Pharmacovigilance Practices (GVP) Module VII – Periodic Safety Update Reports.
4. Commission Implementing Regulation (EU) No 520/2012.
5. Regulation (EC) No 726/2004.
6. Directive 2001/83/EC.
7. ICH E2C(R2) Periodic Benefit-Risk Evaluation Report.
8. CIOMS VIII Practical Aspects of Signal Detection in Pharmacovigilance.